Somewhat Positive News Coverage Somewhat Unlikely to Impact Akebia Therapeutics (AKBA) Stock Price

Headlines about Akebia Therapeutics (NASDAQ:AKBA) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akebia Therapeutics earned a news impact score of 0.03 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.6039178365883 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

AKBA stock traded down $0.05 during mid-day trading on Tuesday, reaching $9.90. 99,869 shares of the company traded hands, compared to its average volume of 439,763. The firm has a market capitalization of $548.22, a PE ratio of -5.59 and a beta of 1.10. Akebia Therapeutics has a 52-week low of $9.00 and a 52-week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Monday, March 12th. The biopharmaceutical company reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.61. The business had revenue of $87.32 million during the quarter, compared to analyst estimates of $66.00 million. Akebia Therapeutics had a negative return on equity of 100.28% and a negative net margin of 43.21%. sell-side analysts expect that Akebia Therapeutics will post -2.63 EPS for the current fiscal year.

Several brokerages have recently issued reports on AKBA. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 15th. BidaskClub lowered Akebia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 15th. Mizuho reaffirmed a “buy” rating and set a $24.00 target price on shares of Akebia Therapeutics in a research report on Tuesday, March 13th. Finally, Piper Jaffray began coverage on Akebia Therapeutics in a research report on Monday, December 18th. They set an “overweight” rating and a $26.00 target price for the company. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $22.20.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply